{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:04Z","timestamp":1787021404875,"version":"build-2736575974"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.1248\/bpb.b25-00565","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T22:11:21Z","timestamp":1772316681000},"page":"414-421","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Various Antibiotics in Bacteremia Caused by AmpC-Producing Enterobacteriaceae, Comparing Carbapenems: A Systematic Review and Network Meta-analysis"],"prefix":"10.1248","volume":"49","author":[{"given":"Satoru","family":"Mitsuboshi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kaetsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Inose","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Uemoto","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Muraki","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Jacoby GA. AmpC B-Lactamases. <i>Clin. Microbiol. Rev.<\/i>, <b>22<\/b>, 161\u2013182 (2009).","DOI":"10.1128\/CMR.00036-08"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hata M, Fujii Y, Tanaka Y, Ishikawa H, Ishii M, Neya S, Tsuda M, Hoshino T. Substrate deacylation mechanisms of serine-\u03b2-lactamases. <i>Biol. Pharm. Bull.<\/i>, <b>29<\/b>, 2151\u20132159 (2006).","DOI":"10.1248\/bpb.29.2151"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections. <i>Clin. Infect. Dis.<\/i>, ciae403 (2024).","DOI":"10.1093\/cid\/ciae403"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world. <i>Clin. Infect. Dis.<\/i>, <b>69<\/b>, 1446\u20131455 (2019).","DOI":"10.1093\/cid\/ciz173"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Aparicio-Minguij\u00f3n E, Fern\u00e1ndez-Ruiz M, San-Juan R, Aguado JM. Which trial do we need? Ceftriaxone <i>vs.<\/i> meropenem for infections due to AmpC-producing Enterobacterales. <i>Clin. Microbiol. Infect.<\/i>, <b>31<\/b>, 1626\u20131629; Online ahead of print (2025).","DOI":"10.1016\/j.cmi.2025.05.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Rahman MK, Rodriguez-Mori H, Loneragan G, Awosile B. One Health distribution of beta-lactamases in Enterobacterales in the United States: a systematic review and meta-analysis. <i>Int. J. Antimicrob. Agents<\/i>, <b>65<\/b>, 107422 (2025).","DOI":"10.1016\/j.ijantimicag.2024.107422"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2-lactamase\u2013producing Enterobacterales, carbapenem-resistant <i>Acinetobacter baumannii<\/i>, and <i>Stenotrophomonas maltophilia<\/i> infections. <i>Clin. Infect. Dis.<\/i>, <b>74<\/b>, 2089\u20132114 (2022).","DOI":"10.1093\/cid\/ciab1013"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Onorato L, de Luca I, Salvati A, Monari C, Coppola N. Piperacillin\/tazobactam <i>vs.<\/i> cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis. <i>Infection<\/i>, <b>53<\/b>, 1141\u20131153 (2024).","DOI":"10.1007\/s15010-024-02447-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Goto R, Inose R, Koizumi R, Sawada K, Ishikane M, Ohmagari N, Muraki Y. Evaluation of the influence of the national action plan on antimicrobial resistance and the COVID-19 pandemic on the consumption of broad-spectrum antimicrobial and anti-methicillin-resistant <i>Staphylococcus aureus<\/i> agents. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 415\u2013421 (2025).","DOI":"10.1248\/bpb.b24-00784"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ohashi K, Shinoda Y, Matsuoka T, Arai K, Hotta N, Takahashi T, Shikano H, Kagajo M, Yagi T, Usami E. Efficacy of enhanced antimicrobial stewardship team interventions for patients receiving meropenem and tazobactam\/piperacillin. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 571\u2013576 (2025).","DOI":"10.1248\/bpb.b24-00862"},{"key":"11","unstructured":"11) Page MJ, McKenzie JE, Bossuyt PM, <i>et al.<\/i> The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ<\/i>, <b>372<\/b>, n71 (2021)."},{"key":"12","unstructured":"12) \u201cRisk of bias tools-ROBINS-I V2 tool\u201d.: \u2039https:\/\/www.riskofbias.info\/welcome\/robins-i-v2\u203a, accessed 31 May, 2025."},{"key":"13","unstructured":"13) Higgins J. James Thomas, Chandler J, Miranda Cumpston, Tianjing Li, Vivian Welch. \u201cCochrane Handbook for Systematic Reviews of Interventions Version 6.5 The Cochrane Collaboration\u201d.: \u2039https:\/\/training.cochrane.org\/handbook\/current\u203a, accessed 9 May, 2024."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. <i>BMJ<\/i>, <b>315<\/b>, 629\u2013634 (1997).","DOI":"10.1136\/bmj.315.7109.629"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shalabi O, Kashat L, Murik O, Zevin S, Assous MV, Ben-Chetrit E. Clinical outcomes of patients with AmpC-beta-lactamase-producing Enterobacterales bacteremia treated with carbapenems <i>versus<\/i> non-carbapenem regimens: a single-center study. <i>Antibiotics<\/i>, <b>13<\/b>, 709 (2024).","DOI":"10.3390\/antibiotics13080709"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Marcos M, I\u00f1urrieta A, Soriano A, Mart\u00ednez JA, Almela M, Marco F, Mensa J. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. <i>J. Antimicrob. Chemother.<\/i>, <b>62<\/b>, 397\u2013403 (2008).","DOI":"10.1093\/jac\/dkn155"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Cheng MP, Lee RS, Cheng AP, De L\u2019\u00c9toile-Morel S, Demir K, Yansouni CP, Harris P, McDonald EG, Lee TC. Beta-lactam\/beta-lactamase inhibitor therapy for potential AmpC-producing organisms: a systematic review and meta-analysis. <i>Open Forum Infect. Dis.<\/i>, <b>6<\/b>, ofz248 (2019).","DOI":"10.1093\/ofid\/ofz248"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Wolter DJ, Schmidtke AJ, Hanson ND, Lister PD. Increased expression of <i>ampC<\/i> in <i>Pseudomonas aeruginosa<\/i> mutants selected with ciprofloxacin. <i>Antimicrob. Agents Chemother.<\/i>, <b>51<\/b>, 2997\u20133000 (2007).","DOI":"10.1128\/AAC.00111-07"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Lee JD, Heintz BH, Mosher HJ, Livorsi DJ, Egge JA, Lund BC. Risk of acute kidney injury and Clostridioides difficile infection with piperacillin\/tazobactam, cefepime, and meropenem with or without vancomycin. <i>Clin. Infect. Dis.<\/i>, <b>73<\/b>, e1579\u2013e1586 (2021).","DOI":"10.1093\/cid\/ciaa1902"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tang Girdwood S, Hasson D, Caldwell JT, Slagle C, Dong S, Fei L, Tang P, Vinks AA, Kaplan J, Goldstein SL. Relationship between piperacillin concentrations, clinical factors and piperacillin\/tazobactam-associated acute kidney injury. <i>J. Antimicrob. Chemother.<\/i>, <b>78<\/b>, 478\u2013487 (2023).","DOI":"10.1093\/jac\/dkac416"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kadomura S, Takekuma Y, Sato Y, Sumi M, Kawamoto K, Itoh T, Sugawara M. Higher incidence of acute kidney injury in patients treated with piperacillin\/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. <i>J. Pharm. Health Care Sci.<\/i>, <b>5<\/b>, 13 (2019).","DOI":"10.1186\/s40780-019-0142-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) \u00c1vila-N\u00fa\u00f1ez M, Lima O, Sousa A, Represa M, Rubi\u00f1\u00e1n P, Celestino P, Garrido-Vent\u00edn M, Garc\u00eda-Formoso L, Vasallo-Vidal F, Martinez-Lamas L, P\u00e9rez-Landeiro A, Rubianes M, P\u00e9rez-Rodr\u00edguez M. Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing Enterobacterales. <i>Ann. Clin. Microbiol. Antimicrob.<\/i>, <b>22<\/b>, 75 (2023).","DOI":"10.1186\/s12941-023-00624-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chaubey VP, Pitout JDD, Dalton B, Gregson DB, Ross T, Laupland KB. Clinical and microbiological characteristics of bloodstream infections due to AmpC \u03b2-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. <i>BMC Infect. Dis.<\/i>, <b>14<\/b>, 647 (2014).","DOI":"10.1186\/s12879-014-0647-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Herrmann J, Burgener-Gasser AV, Goldenberger D, Roth J, Weisser M, Tamma PD, Tschudin-Sutter S. Cefepime <i>versus<\/i> carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections. <i>Eur. J. Clin. Microbiol. Infect. Dis.<\/i>, <b>43<\/b>, 213\u2013221 (2024).","DOI":"10.1007\/s10096-023-04715-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM, Bonomo RA, M\u00fchlemann K, Endimiani A. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? <i>Int. J. Antimicrob. Agents<\/i>, <b>41<\/b>, 236\u2013249 (2013).","DOI":"10.1016\/j.ijantimicag.2012.10.022"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hoellinger B, Kaeuffer C, Boyer P, Lefebvre N, Hansmann Y, Robert A, Severac F, Gravet A, Danion F, Ruch Y, Ursenbach A. Cefepime <i>vs.<\/i> carbapenems for treating third-generation cephalosporin-resistant AmpC \u03b2-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study. <i>Int. J. Infect. Dis.<\/i>, <b>134<\/b>, 273\u2013279 (2023).","DOI":"10.1016\/j.ijid.2023.07.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kunz Coyne AJ, El Ghali A, Lucas K, Witucki P, Rebold N, Holger DJ, Veve MP, Rybak MJ. High-dose cefepime <i>vs.<\/i> carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC \u03b2-lactamase production. <i>Open Forum Infect. Dis.<\/i>, <b>10<\/b>, ofad034 (2023).","DOI":"10.1093\/ofid\/ofad034"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) McKamey L, Venugopalan V, Cherabuddi K, Borgert S, Voils S, Shah K, Klinker KP. Assessing antimicrobial stewardship initiatives: clinical evaluation of cefepime or piperacillin\/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. <i>Int. J. Antimicrob. Agents<\/i>, <b>52<\/b>, 719\u2013723 (2018).","DOI":"10.1016\/j.ijantimicag.2018.08.007"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim H, Kim EC, Oh MD, Choe KW. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-\u03b2-lactamase-producing <i>Klebsiella pneumoniae.<\/i> <i>Antimicrob. Agents Chemother.<\/i>, <b>48<\/b>, 3720\u20133728 (2004).","DOI":"10.1128\/AAC.48.10.3720-3728.2004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Stewart AG, Paterson DL, Young B, <i>et al.<\/i> Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC \u03b2-lactamase\u2013producing <i>Enterobacter<\/i> spp, <i>Citrobacter freundii<\/i>, <i>Morganella morganii<\/i>, <i>Providencia<\/i> spp, or <i>Serratia marcescens<\/i>: a pilot multicenter randomized controlled trial (MERINO-2). <i>Open Forum Infect. Dis.<\/i>, <b>8<\/b>, ofab387 (2021).","DOI":"10.1093\/ofid\/ofab387"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Tan SH, Ng TM, Chew KL, Yong J, Wu JE, Yap MY, Heng ST, Ng WHW, Wan S, Cheok SJH, Tambyah PA, Lye DC. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems <i>vs.<\/i> non-carbapenems. <i>Int. J. Antimicrob. Agents<\/i>, <b>55<\/b>, 105860 (2020).","DOI":"10.1016\/j.ijantimicag.2019.105860"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00565\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:01:38Z","timestamp":1772856098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00565\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00565","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"b25-00565"}}